Loading...
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
Torge, Afra Wagner, Stefanie Chaves, Paula S Oliveira, Edilene G Guterres, Silvia S Pohlmann, Adriana R Beck, Ruy C R
Torge, Afra
Wagner, Stefanie
Chaves, Paula S
Oliveira, Edilene G
Guterres, Silvia S
Pohlmann, Adriana R
Beck, Ruy C R
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2017-05-10
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 31.12 MB
Other Titles
Abstract
Treatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biological barrier, ciprofloxacin was loaded into lipid-core nanocapsules (LNC) for high mucus permeability, sustained release and antibacterial activity. Ciprofloxacin-loaded LNC with a mean size of 180nm showed a by 50% increased drug permeation through mucus. In bacterial growth assays, the drug in the LNC had similar minimum inhibitory concentrations as the free drug in P. aeruginosa and S. aureus. Interestingly, formation of biofilm-like aggregates, which were observed for S. aureus treated with free ciprofloxacin, was avoided by exposure to LNC. With the combined advantages over the non-encapsulated drug, ciprofloxacin-loaded LNC represent a promising drug delivery system with the prospect of an improved antibiotic therapy in cystic fibrosis.
Citation
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. 2017, 527 (1-2):92-102 Int J Pharm
Publisher
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1873-3476